根据需要使用药物来激发整个烯酸配方的激发
Michael Ley1,2, Casey Tiefenthaler1, Jamie Kneebusch3
1Department of Pharmacy, UC San Diego Health, San Diego, California.
Current therapeutic research, clinical and experimental
|February 25, 2026
概括
酸 (VPA) 配方对双相I型和精神分裂症的症状控制有影响. 延长释放的VPA可能会减少对必要的二胺和抗精神病剂剂量的需求.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 临床治疗学 临床治疗学
背景情况:
- 立即释放 (IR),延迟释放 (DR) 和延长释放 (ER) 烯酸 (VPA) 配方之间存在药理学变化.
- 这些药理动力学差异可能会影响治疗疗效和患者的治疗结果.
- 按需要 (pro re nata,PRN) 药物可以作为治疗兴奋症的计划药物有效性的指标.
研究的目的:
- 为了比较不同VPA配方 (IR,DR,ER) 中用于激发的PRN二甲和抗精神病剂的数量.
- 调查VPA配方与双相I型或精神分裂情绪障碍患者需要PRN药物的相关性.
主要方法:
- 对150名患有双相I型或精神分裂情绪障碍,接受维护VPA治疗的患者进行了回顾性审查.
- 主要结局:平均每日PRN二甲和/或抗精神病剂剂量用于激发.
- 二次结局:VPA的总日剂量 (TDD). 统计分析包括ANOVA和分层多重回归.
主要成果:
- VPA配方与每日PRN抗精神病药物和/或二二胺剂量 (包括单独抗精神病药物) 的平均值有显著的相关性.
- 在调整了诸如年龄,性别,种族和VPA TDD等混因素后,这些关联仍然显著.
结论:
- VPA的配方显著影响了对PRN药物的要求,以管理激动.
- 这些发现表明症状控制中的配方依赖差异,需要进一步调查心理疾病的最佳VPA输送.
相关概念视频
Mania and Antimanic Drugs: Overview
706
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
706
Dosage Regimen: Individualization
230
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
230
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K
Dosage Regimen: Fixed Dose
2.5K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.5K
Drug Dosage Regimen: Overview
4.6K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.6K
Dosage Regimens: Partial Pharmacokinetic Parameters
226
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
226


